Research uncovers Blautia bacteria’s crucial role in gut health and disease protection

FHS
April 29, 2024
11:29 am

A low-fiber “Western diet” causes damage to the protective mucus barrier in the gut, and such damage can increase the risk of inflammation and infection.

Risk adjusted net present value: What is the current valuation of Kymera Therapeutics’s KT-413?

KT-413 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Primary CNS Lymphoma.

November 20, 2023

How telehealth startups are trying to fill the menopause care vacuum

At the turn of the century, nearly 18 million women in the United States were battling hot flashes, night sweats, and other symptoms of menopause

July 17, 2023

EuroAPI’s blueprint for ‘leaner’ operations includes dropping products, potential layoffs and sites put on ice

EuroAPI is counting on 2024 to be its “year of transition” as the small molecule producer plans to discontinue API assets, potentially make layoffs and

March 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.